B4GALT1 Antibody

Basic Research Questions

• What is B4GALT1 and what are the optimal antibody selection criteria for its detection?

  B4GALT1 is one of seven beta-1,4-galactosyltransferases that transfer galactose in a beta-1,4 linkage to acceptor sugars including GlcNAc, Glc, and Xyl . It is unique among the beta-4-GalT family because it participates in both glycoconjugate and lactose biosynthesis . When selecting antibodies, consider the following criteria:

  • Epitope recognition: Choose antibodies targeting either N-terminal or C-terminal regions based on your research question. C-terminal antibodies (e.g., ABIN6259493) are particularly useful for detecting the full-length protein .

  • Host species: Rabbit polyclonal antibodies show good reactivity against human and mouse B4GALT1 .

  • Application compatibility: Verify the antibody is validated for your specific application (WB, IHC, ICC, IF) .

  Antibody Type	Common Applications	Species Reactivity	Epitope Region
  Polyclonal	WB, IHC, ICC, IF	Human, Mouse	C-Terminal
  Monoclonal	WB, FACS	Human	Various

• What cellular compartments does B4GALT1 localize to and how should immunostaining be optimized?

  B4GALT1 exhibits dual localization: primarily in the Golgi apparatus and on the cell surface . The membrane form can reside either in the Golgi apparatus, where it adds galactose to N-acetylglucosamine residues, or on the cell surface, where it functions as a recognition molecule during cell-cell and cell-matrix interactions . Optimize immunostaining by:

  • Using permeabilization protocols compatible with Golgi proteins

  • Employing organelle co-markers (Golgi markers like GM130)

  • Capturing high-resolution images of the perinuclear region

  • Implementing a low-detergent fixation protocol for surface staining

  Immunofluorescence data shows specific staining localized to the cytoplasm, particularly in the Golgi region, as demonstrated in HeLa cells .

• How can researchers validate B4GALT1 antibody specificity?

  Validation is crucial for ensuring experimental rigor. Multiple approaches include:

  • Peptide competition assays: The antiserum for B4GALT1 antibodies can be validated through peptide affinity chromatography using SulfoLink Coupling Resin .

  • Knockdown/knockout validation: As demonstrated in HCC research, B4GALT1 knockout with CRISPR/Cas9 systems confirms antibody specificity through the disappearance of target bands .

  • Multiple antibody comparison: Using two independent antibodies with non-overlapping epitopes. When similar staining patterns are observed across main and additional locations, this provides enhanced antibody validation .

  • Western blot analysis: Verifying a single band at the expected molecular weight (approximately 44 kDa) .

• What are the common applications for B4GALT1 antibodies in glycobiology research?

  B4GALT1 antibodies support multiple experimental applications in glycobiology:

  • Western Blotting (WB): For quantitative assessment of B4GALT1 expression levels

  • Immunohistochemistry (IHC): For examining tissue localization patterns

  • Immunocytochemistry (ICC)/Immunofluorescence (IF): For subcellular localization studies

  • ELISA: For quantitative measurement in biological samples

  • Flow Cytometry: For cell surface expression analysis

  The choice of application should be guided by experimental goals and sample types. For example, IHC is preferable for examining B4GALT1 distribution in tissue microarrays, while flow cytometry is optimal for quantifying cell surface expression.

Advanced Research Questions

• How can B4GALT1 antibodies be used to investigate glycosylation changes in cancer progression?

  B4GALT1 expression varies significantly across cancer types, requiring tailored experimental approaches:

  • For leukemia (LAML): High expression of B4GALT1 is associated with poor prognosis, unfavorable cytogenetic risk, and NPM1 mutation . Use B4GALT1 antibodies for:

    • Stratifying patient samples by expression levels

    • Correlating with clinical markers (cytogenetic risk, NPM1 mutation status)

    • Monitoring treatment response

  • For hepatocellular carcinoma (HCC): Decreased B4GALT1 promotes invasiveness . Implement:

    • Invasion/migration assays following B4GALT1 knockdown/overexpression

    • Glycan profiling of cell surface proteins

    • Co-immunoprecipitation with integrin partners

  Research has shown that B4GALT1 is significantly elevated in patients with non-M3 leukemia and is associated with intermediate/poor cytogenetic risk (OR, 0.256; p=0.002) .

• What methodological approaches can identify glycoprotein substrates modified by B4GALT1?

  Identifying B4GALT1 substrates requires specialized glycoproteomic techniques:

  • Lectin pull-down assays: GSL-II pull-down assays identified integrins α6 and β1 as main protein substrates of B4GALT1 .

  • Glycoproteomics workflow:

    1. Metabolic labeling with galactose analogs

    2. Click chemistry for enrichment of labeled glycoproteins

    3. Mass spectrometry identification

    4. Validation with B4GALT1 knockout/knockdown models

  • Glycan structure analysis: Compare glycan profiles between control and B4GALT1-depleted samples using:

    • HPLC analysis of fluorescently labeled glycans

    • Mass spectrometry of released glycans

    • Lectin microarray profiling

  Research demonstrated that B4GALT1 downregulation alters N-glycosylation and enhances the laminin-binding activity of integrin α6 and integrin β1 to promote invasiveness of HCC cells .

• How can researchers investigate B4GALT1's role in immune regulation using antibody-based approaches?

  B4GALT1 may influence tumor immune microenvironment through multiple mechanisms:

  • Immune infiltration analysis:

    • Combine B4GALT1 immunostaining with immune cell markers

    • Quantify correlation between B4GALT1 expression and immune cell abundance

    • Assess relationship with PD-L1 glycosylation status

  • Functional assays:

    1. Co-culture tumor cells with immune cells following B4GALT1 manipulation

    2. Measure cytokine production, immune cell activation, and cytotoxicity

    3. Analyze glycosylation of immune checkpoint molecules

  Recent studies suggest that B4GALT1 may influence tumor immune escape by affecting the abundance of Macrophages, Treg cells, and Th17 cells, which were significantly increased in the high B4GALT1 expression group . Additionally, B4GALT1 has been identified as a PD-L1 glycosyltransferase in triple-negative breast cancer .

• What are the best experimental strategies to distinguish between membrane-bound and secreted forms of B4GALT1?

  B4GALT1 exists in both membrane-bound and secreted forms, requiring distinct detection methods:

  • Membrane-bound form detection:

    • Surface biotinylation followed by pull-down

    • Cell fractionation with Golgi markers

    • Non-permeabilized immunofluorescence

  • Secreted form detection:

    • ELISA of conditioned media

    • Immunoprecipitation from culture supernatants

    • Western blotting of concentrated media

  • Differential analysis:

    • Use antibodies specific to different domains (N-terminal vs. C-terminal)

    • Utilize glycosylation status as marker for secreted vs. membrane forms

    • Perform comparative studies in lactating mammary tissue (where secreted form predominates)

  The membrane form resides either in the Golgi apparatus or on the cell surface, while the secreted form is primarily found in body fluids, particularly in lactating mammary tissues where it forms a heterodimer with alpha-lactalbumin to catalyze lactose synthesis .

• How can researchers design functional studies to investigate B4GALT1's role in cell adhesion and migration?

  Investigating B4GALT1's role in cell behavior requires multi-faceted approaches:

  • Adhesion studies:

    1. Perform adhesion assays on different ECM components (laminin, fibronectin)

    2. Blocking antibody experiments against B4GALT1 and integrin partners

    3. Compare wild-type vs. catalytically inactive B4GALT1 mutants

  • Migration analyses:

    • Wound healing assays with B4GALT1 knockdown/overexpression

    • Transwell migration with glycosylation inhibitors

    • Live cell imaging to track migration dynamics

  • In vivo validation:

    • Tail vein injection of B4GALT1 knockout cells to assess metastatic potential

    • Orthotopic models with manipulated B4GALT1 expression

  Research has shown that B4GALT1 knockout enhanced lung metastasis of PLC5 cells in experimental metastatic models, consistent with its role in regulating cell invasion .

• What approaches can resolve contradictory findings regarding B4GALT1 expression across different cancer types?

  Different cancer types show opposite patterns of B4GALT1 expression and function:

  • Contradictory findings resolution:

    • Perform context-dependent analyses across multiple cancer types

    • Investigate expression at different disease stages

    • Consider cellular heterogeneity within tumor samples

  • Experimental design strategies:

    • Analyze matched normal/tumor pairs from the same patient

    • Correlate with glycome changes specific to each cancer type

    • Examine impact of tumor microenvironment on B4GALT1 expression

  • Potential explanations for contradictions:

    • Tissue-specific roles of glycosylation patterns

    • Differential substrate availability across tissues

    • Compensatory mechanisms involving other glycosyltransferases

  Research has demonstrated that high B4GALT1 expression correlates with poor prognosis in leukemia (LAML) , while decreased B4GALT1 expression is associated with poor outcomes in hepatocellular carcinoma (HCC) , highlighting the context-dependent role of this enzyme in different cancer types.